ArticleClinical drug investigation2013

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.

Wenhui Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.